迷走神経刺激装置(VNS):医療機器パイプライン分析

◆英語タイトル:Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0150
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥848,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD12,000 ⇒換算¥1,272,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Vagus Nerve Stimulators (VNS) – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Vagus Nerve Stimulators (VNS) – Medical Devices Pipeline Assessment, 2019″ provides an overview of Vagus Nerve Stimulators (VNS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators (VNS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Vagus Nerve Stimulators (VNS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Vagus Nerve Stimulators (VNS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Vagus Nerve Stimulators (VNS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Vagus Nerve Stimulators (VNS) Overview 8
3 Products under Development 9
3.1 Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development 9
3.2 Vagus Nerve Stimulators (VNS) – Pipeline Products by Territory 10
3.3 Vagus Nerve Stimulators (VNS) – Pipeline Products by Regulatory Path 11
3.4 Vagus Nerve Stimulators (VNS) – Pipeline Products by Estimated Approval Date 12
3.5 Vagus Nerve Stimulators (VNS) – Ongoing Clinical Trials 13
4 Vagus Nerve Stimulators (VNS) – Pipeline Products under Development by Companies 14
4.1 Vagus Nerve Stimulators (VNS) Companies – Pipeline Products by Stage of Development 14
4.2 Vagus Nerve Stimulators (VNS) – Pipeline Products by Stage of Development 15
5 Vagus Nerve Stimulators (VNS) Companies and Product Overview 17
5.1 Aucta Technologies Inc Company Overview 17
5.1.1 Aucta Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Boston Scientific Corp Company Overview 20
5.2.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Cala Health Inc Company Overview 24
5.3.1 Cala Health Inc Pipeline Products & Ongoing Clinical Trials Overview 24
5.4 CerboMed GmbH Company Overview 25
5.4.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 25
5.5 Cyberonics Inc Company Overview 26
5.5.1 Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.6 DuoCure Ltd. Company Overview 27
5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27
5.7 ElectroCore Inc Company Overview 28
5.7.1 ElectroCore Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.8 LivaNova PLC Company Overview 33
5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 33
5.9 Medical University of South Carolina Company Overview 42
5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 42
5.10 MicroTransponder Inc Company Overview 43
5.10.1 MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.11 Nexeon MedSystems Inc Company Overview 48
5.11.1 Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview 48
5.12 Otto Bock HealthCare GmbH Company Overview 50
5.12.1 Otto Bock HealthCare GmbH Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Parasym Ltd Company Overview 52
5.13.1 Parasym Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Pulsus Medical LLC (Inactive) Company Overview 55
5.14.1 Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 55
5.15 Purdue University Company Overview 56
5.15.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 56
5.16 Setpoint Medical Inc Company Overview 57
5.16.1 Setpoint Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 57
5.17 Synergia Medical Company Overview 60
5.17.1 Synergia Medical Pipeline Products & Ongoing Clinical Trials Overview 60
5.18 SzeleSTIM GmbH Company Overview 61
5.18.1 SzeleSTIM GmbH Pipeline Products & Ongoing Clinical Trials Overview 61
5.19 The Feinstein Institute for Medical Research Company Overview 62
5.19.1 The Feinstein Institute for Medical Research Pipeline Products & Ongoing Clinical Trials Overview 62
5.20 Trifectas Medical Corp. Company Overview 67
5.20.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 67
5.21 University of Pittsburgh Company Overview 68
5.21.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 68
5.22 University of Wisconsin Madison Company Overview 69
5.22.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 69
6 Vagus Nerve Stimulators (VNS)- Recent Developments 70
6.1 Nov 13, 2019: electroCore announces third quarter 2019 financial results 70
6.2 Oct 30, 2019: LivaNova reports third quarter 2019 results 71
6.3 Oct 29, 2019: SetPoint Medical announces oral presentation of results from U.S. pilot study in rheumatoid arthritis patients at American College of Rheumatology (ACR) Annual Meeting 2019 72
6.4 Oct 23, 2019: Study published in Neurology shows chronic epilepsy associated with marker of cardiac electrical instability 72
6.5 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 73
7 Appendix 118
7.1 Methodology 118
7.2 About GlobalData 121
7.3 Contact Us 121
7.4 Disclaimer 121

List of Tables
Table 1: Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Table 2: Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory
Table 3: Vagus Nerve Stimulators (VNS) - Pipeline Products by Regulatory Path
Table 4: Vagus Nerve Stimulators (VNS) - Pipeline Products by Estimated Approval Date
Table 5: Vagus Nerve Stimulators (VNS) - Ongoing Clinical Trials
Table 6: Vagus Nerve Stimulators (VNS) Companies - Pipeline Products by Stage of Development
Table 7: Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Table 8: Aucta Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: DECIMA Device - Product Status
Table 10: DECIMA Device - Product Description
Table 11: Aucta Technologies Inc - Ongoing Clinical Trials Overview
Table 12: DECIMA Device - This is a Single-site, Double-blind, Randomized, Prospective, Sham-controlled, Crossover Early Feasibility Study to Determine Whether Ultrasound Vagus Nerve Stimulation (uVNS) Inhibits Postprandial Hyperglycemia in Humans
Table 13: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 14: AMT System - Product Status
Table 15: AMT System - Product Description
Table 16: Vagus Nerve Stimulation (VNS) System - Product Status
Table 17: Vagus Nerve Stimulation (VNS) System - Product Description
Table 18: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 19: Vagus Nerve Stimulation (VNS) System - Neural Cardiac Therapy for Heart Failure Study
Table 20: Cala Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Wearable Neuromodulation Device - Product Status
Table 22: Wearable Neuromodulation Device - Product Description
Table 23: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 24: t-VNS - Dementia - Product Status
Table 25: t-VNS - Dementia - Product Description
Table 26: Cyberonics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Nerve Wrap - Product Status
Table 28: Nerve Wrap - Product Description
Table 29: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Intraluminal Implantable Device - Product Status
Table 31: Intraluminal Implantable Device - Product Description
Table 32: ElectroCore Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 33: GammaCore - Gastroenterology - Product Status
Table 34: GammaCore - Gastroenterology - Product Description
Table 35: gammaCore - Migraine Prevention - Product Status
Table 36: gammaCore - Migraine Prevention - Product Description
Table 37: GammaCore - Neurology - Product Status
Table 38: GammaCore - Neurology - Product Description
Table 39: GammaCore - Post-Traumatic Headache - Product Status
Table 40: GammaCore - Post-Traumatic Headache - Product Description
Table 41: GammaCore - Rheumatoid Arthritis - Product Status
Table 42: GammaCore - Rheumatoid Arthritis - Product Description
Table 43: GammaCore - Sjogren’s Syndrome - Product Status
Table 44: GammaCore - Sjogren’s Syndrome - Product Description
Table 45: Resolve Stimulator - Product Status
Table 46: Resolve Stimulator - Product Description
Table 47: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Aspire NP - Product Status
Table 49: Aspire NP - Product Description
Table 50: Centro Generator - Product Status
Table 51: Centro Generator - Product Description
Table 52: CentroSR Generator - Product Status
Table 53: CentroSR Generator - Product Description
Table 54: Equilia - Product Status
Table 55: Equilia - Product Description
Table 56: Griffin - Pulse Generator - Product Status
Table 57: Griffin - Pulse Generator - Product Description
Table 58: Intense Neuromodulation System - Heart Failure - Product Status
Table 59: Intense Neuromodulation System - Heart Failure - Product Description
Table 60: Microburst VNS Stimulator - Product Status
Table 61: Microburst VNS Stimulator - Product Description
Table 62: PhoenixRF SR - Product Status
Table 63: PhoenixRF SR - Product Description
Table 64: VITARIA System - Chronic Heart Failure - Product Status
Table 65: VITARIA System - Chronic Heart Failure - Product Description
Table 66: LivaNova PLC - Ongoing Clinical Trials Overview
Table 67: VITARIA System - Chronic Heart Failure - Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Reduced Ejection Fraction
Table 68: Microburst VNS Stimulator - Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy
Table 69: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status
Table 71: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description

List of Figures
Figure 1: Vagus Nerve Stimulators (VNS) - Pipeline Products by Stage of Development
Figure 2: Vagus Nerve Stimulators (VNS) - Pipeline Products by Territory
Figure 3: Vagus Nerve Stimulators (VNS) - Pipeline Products by Regulatory Path
Figure 4: Vagus Nerve Stimulators (VNS) - Pipeline Products by Estimated Approval Date
Figure 5: Vagus Nerve Stimulators (VNS) - Ongoing Clinical Trials

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[迷走神経刺激装置(VNS):医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆